Skip to main content

Regeneron Pharmaceuticals cash flow statement

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

In fiscal 2025 (the year to 31 Dec 2025), Regeneron Pharmaceuticals generated $4.98B of operating cash flow and $4.08B of free cash flow, after $898.4M of capital expenditure.

From Regeneron Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Regeneron Pharmaceuticals cash flow statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income−$79.13M−$67.83M−$104.5M−$221.8M$750.3M$413.7M$338.1M$636.1M$895.5M$1.20B$2.44B$2.12B$3.51B$8.08B$4.34B$3.95B$4.41B$4.50B$4.82B
Depreciation & amortization$11.29M$14.20M$19.69M$31.08M$36.94M$41.20M$52.69M$74.91M$104.7M$145.5M$148.2M$210.3M$235.9M$286.2M$341.4M$421.0M$482.9M$543.7M$512.9M
Stock-based compensation$32.52M$31.26M$39.90M$56.09M$94.16M$215.4M$321.8M$459.0M$559.9M$507.3M$427.4M$464.3M$432.0M$601.7M$725.0M$885.0M$982.8M$993.7M$1.01B
Operating cash flow−$89.09M−$69.94M$99.22M−$141.7M−$74.61M$588.6M$752.4M$1.33B$1.49B$1.31B$2.20B$2.43B$2.62B$7.08B$5.01B$4.59B$4.42B$4.98B$4.85B
Operating cash flow margin−37.4%−18.4%21.6%−31.8%−5.4%28.0%26.7%32.4%30.6%22.3%42.7%37.1%30.8%44.1%41.2%35.0%31.1%34.7%28.7%
Capital expenditures$34.86M$97.32M$99.69M$57.22M$49.34M$156.3M$333.0M$677.9M$511.9M$272.6M$383.1M$429.6M$614.6M$551.9M$590.1M$718.6M$755.9M$898.4M$1.02B
Acquisitions—————————————$0.00$230.3M$54.90M$16.50M$3.30M—
Free cash flow−$123.9M−$167.3M−$467.0K−$198.9M−$124.0M$432.3M$419.4M$652.8M$974.0M$1.03B$1.81B$2.00B$2.00B$6.53B$4.42B$3.88B$3.66B$4.08B$3.83B
Free cash flow margin−52.0%−44.1%−0.1%−44.6%−9.0%20.5%14.9%15.9%20.0%17.6%35.2%30.5%23.6%40.6%36.3%29.5%25.8%28.4%22.6%
Free cash flow per share——−$0.01−$2.20−$1.07$3.88$3.70$5.67$8.37$8.93$15.78$17.46$17.41$58.19$38.99$34.08$31.84$37.57$35.84
Dividends paid———————————————$0.00$0.00$370.3M$383.0M
Gross share repurchases————————$0.00$0.00$4.40M$275.9M$5.85B$1.65B$2.08B$2.23B$2.60B$3.44B$3.04B
Stock issuance proceeds$7.95M$8.60M$200.6M$43.59M$63.55M$57.39M$126.0M$206.4M$126.7M$240.2M$114.5M$211.8M$2.58B$1.67B$1.52B$1.15B$1.47B$635.9M$1.02B
Net share repurchases−$7.95M−$8.60M−$200.6M−$43.59M−$63.55M−$57.39M−$126.0M−$206.4M−$126.7M−$240.2M−$110.1M$64.10M$3.27B−$26.90M$563.3M$1.09B$1.14B$2.80B$2.02B
Cash interest paid$9.35M$2.52M$12.74M$14.72M$21.95M$23.20M$20.35M$10.58M$5.50M$18.70M$22.30M$25.00M$23.20M$55.80M$53.70M$73.10M$52.60M$41.60M—
Free cash flow after SBC−$156.5M−$198.5M−$40.36M−$255.0M−$218.1M$216.9M$97.68M$193.8M$414.1M$527.2M$1.38B$1.54B$1.57B$5.93B$3.70B$2.99B$2.68B$3.09B$2.82B

Quarterly

Regeneron Pharmaceuticals cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income$1.16B$722.0M$1.43B$1.34B$917.7M$808.7M$1.39B$1.46B$844.6M$727.2M$1.30B$1.95B
Depreciation & amortization$113.0M$114.1M$120.7M$121.7M$126.4M$126.9M$135.1M$136.7M$145.0M$123.2M$123.7M$121.0M
Stock-based compensation$240.4M$230.1M$223.2M$225.1M$304.4M$255.7M$251.7M$237.0M$249.3M$257.4M$243.0M$255.8M
Operating cash flow$1.09B$1.51B$354.0M$1.29B$1.26B$1.05B$1.14B$1.62B$1.17B$1.08B$813.0M$1.78B
Operating cash flow margin31.7%48.1%10.0%34.7%33.3%34.5%31.1%43.1%30.1%29.9%18.9%34.9%
Capital expenditures$251.4M$133.9M$180.5M$241.9M$199.6M$229.3M$219.0M$201.4M$248.7M$230.6M$240.2M$300.2M
Acquisitions$3.80M——$0.00$11.50M——$3.00M$300.0K———
Free cash flow$838.3M$1.38B$173.5M$1.05B$1.06B$815.8M$925.4M$1.42B$922.0M$848.3M$572.8M$1.48B
Free cash flow margin24.4%43.8%4.9%28.2%28.1%26.9%25.2%37.8%23.7%23.5%13.3%29.0%
Free cash flow per share$7.37$11.98$1.50$9.03$9.36$7.34$8.52$13.22$8.56$7.88$5.40$14.05
Dividends paid—$0.00$0.00$0.00$0.00$93.80M$92.60M$91.20M$92.70M$97.80M$96.80M$95.70M
Gross share repurchases$289.0M$291.3M$603.9M$735.1M$973.0M$1.04B$1.06B$664.0M$671.7M$794.3M$1.17B$399.7M
Stock issuance proceeds$301.0M$682.1M$437.6M$254.7M$90.90M$60.60M$31.50M$40.30M$503.5M$163.1M$49.20M$300.9M
Net share repurchases−$12.00M−$390.8M$166.3M$480.4M$882.1M$980.8M$1.03B$623.7M$168.2M$631.2M$1.12B$98.80M
Free cash flow after SBC$597.9M$1.15B−$49.70M$824.2M$758.8M$560.1M$673.7M$1.18B$672.7M$590.9M$329.8M$1.23B

The main figures as JSON and plain text. See data and methodology.

REGN in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.